Stockreport

SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

SOPHiA GENETICS SA - Ordinary Shares  (SOPH) 
PDF The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEOBOSTON and ROLLE, Switzerland, Jan. 12, 2026 / [Read more]